Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).
Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).
It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).
It is very uncertain whether the intervention changes adverse events－serious events Budesonide/formoterol (BDF) versus… (very low certainty).
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).